Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.00M
Last updated: Nov 17, 2026 at 4:33 PM ET
Traws Pharma Inc (TRAW) Stock Chart
Traws Pharma (TRAW) has a latest price of $0.24 on Nov 17, 2026, 92.0% below its 52-week high of $2.98. Its price fell 89.0% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 65.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $17,082.91 in Mar 2017 and its lowest $0.30 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TRAW with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TRAW.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 55.8%, and over 6 months it fell 85.0%. The month-end price fell 98.2% over the 3 years through Oct 2026, a compound annual decline of 73.6%.
| Period | Change |
|---|---|
| 1 month | -34.9% |
| 3 months | -55.8% |
| 6 months | -85.0% |
| 12 months | -89.0% |
| 12 months, with dividends | -89.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -98.2% | -73.6% |
| 5 years | -99.7% | -67.9% |
| 10 years | -100.0% | -65.9% |
Price by Year
Its best calendar year was 2020, when the price rose 22.6%, and its weakest was 2018, when it fell 90.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.30 | -73.8% |
| 2025 | $1.13 | -87.3% |
| 2024 | $8.88 | -52.4% |
| 2023 | $18.64 | +15.5% |
| 2022 | $16.14 | -74.7% |
| 2021 | $63.75 | -63.5% |
| 2020 | $174.59 | +22.6% |
| 2019 | $142.43 | -82.0% |
| 2018 | $790.85 | -90.6% |
| 2017 | $8,429.07 | -33.9% |
Trading Range
The price is 42.6% below its 50-day average of $0.42 and 77.1% below its 200-day average of $1.04.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.24 | |
| 52-week high | $2.98 | -92.0% |
| 52-week low | $0.22 | +9.0% |
| 50-day average | $0.42 | -42.6% |
| 200-day average | $1.04 | -77.1% |
Price Risk
Over 3 years, its largest fall from a peak was 99.1%.
| Measure | Value |
|---|---|
| 1-year beta | 1.61 |
| Largest fall, 1 year | -92.2% |
| Largest fall, 3 years | -99.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TRAW
What is TRAW's 1-year price change?
Traws Pharma's price fell 89.0% over the past 12 months. With dividends included, the 12-month total return was -89.0%.
What is TRAW's 5-year price change?
Traws Pharma's month-end price fell 99.7% over the 5 years through Oct 2026, a compound annual decline of 67.9%. These figures leave out dividends.
What is TRAW's 52-week high and low?
Traws Pharma's 52-week high is $2.98 and its 52-week low is $0.22. Its latest price of $0.24 on Nov 17, 2026 is 92.0% below the high.
What is TRAW's beta?
Traws Pharma's 1-year beta against the S&P 500 is 1.61, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 92.2%.
Is the TRAW chart free?
Yes. Advanced Charting for TRAW is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TRAW pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors